Degenerate Titelbild

Degenerate

Reinhören
0,00 € - kostenlos hören
Prime Logo Bist du Amazon Prime-Mitglied?
Audible 60 Tage kostenlos testen
Aktiviere das kostenlose Probeabo mit der Option, monatlich flexibel zu pausieren oder zu kündigen.
Nach dem Probemonat bekommst du eine vielfältige Auswahl an Hörbüchern, Kinderhörspielen und Original Podcasts für 9,95 € pro Monat.
Wähle monatlich einen Titel aus dem Gesamtkatalog und behalte ihn.

Degenerate

Von: Matt Casamassina
Gesprochen von: Phillip Nathaniel Freeman
0,00 € - kostenlos hören

9,95 € pro Monat nach 30 Tagen. Monatlich kündbar.

Für 25,95 € kaufen

Für 25,95 € kaufen

Über diesen Titel

The latest novel from Matt Casamassina, author of Sophistication, which Kirkus Reviews called "Ambitious. Well-paced. Riveting. [Casamassina] occasionally reaches moments of lyricism.”

Mason Kowalski, a twenty-four year-old copywriter for a San Mateo startup, is on the verge of a nervous breakdown when he inexplicably suffers widespread vision loss in one eye. The doctors say it’s macular degeneration triggered by overwhelming stress, but he wonders if it’s something more, especially when the shadows in his peripheral vision begin to take shape and whisper wonderful and horrible things to him. Is it madness or destiny? The answer could destroy everything and everyone he holds dear.

Journey into the absurd beating heart of Silicon Valley as Mason and his lovable friends try to stop a demented serial killer from murdering more children. Degenerate mashes horror and sci-fi into a twisted, dark, violent and funny pulp drowned in tentacled nightmares. Featuring infamous hijacker DB Cooper and more twists than you can imagine, the genre-breaking story is designed for fans of Stephen King, Blake Crouch, Peter Clines, Keith Rosson, Chuck Wendig and John Scalzi.

©2025 Matt Casamassina (P)2025 Matt Casamassina
Postapokalyptisch Science Fiction

Kritikerstimmen

“As ambitious as it is unpredictable.” - Kirkus Reviews

“A resolutely unclassifiable epic from Casamassina that blends genres into the wildest of elixirs.” - Publishers Weekly

Noch keine Rezensionen vorhanden